UA97629C2 - Фармацевтическая композиция, имеющая противоопухолевую активность, и способы - Google Patents

Фармацевтическая композиция, имеющая противоопухолевую активность, и способы

Info

Publication number
UA97629C2
UA97629C2 UAA200807478A UAA200807478A UA97629C2 UA 97629 C2 UA97629 C2 UA 97629C2 UA A200807478 A UAA200807478 A UA A200807478A UA A200807478 A UAA200807478 A UA A200807478A UA 97629 C2 UA97629 C2 UA 97629C2
Authority
UA
Ukraine
Prior art keywords
methods
pharmaceutical formulation
antitumor activity
formulation exhibiting
exhibiting antitumor
Prior art date
Application number
UAA200807478A
Other languages
English (en)
Ukrainian (uk)
Inventor
Сальве Пилар Кальво
Баррейра Мария Тобио
Original Assignee
Фарма Мар, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарма Мар, С.А. filed Critical Фарма Мар, С.А.
Publication of UA97629C2 publication Critical patent/UA97629C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к области фармацевтики и медицины и касается фармацевтической композиции, имеющей противоопухолевую активность, содержащей соединение, родственное джорумицину, рениерамицину, сафрацину и сафрамицину, и дисахарид. Изобретение также касается флакона, заполненного лиофилизированной композицией, способа получения раствора для внутривенной инфузии и способа лечения рака.
UAA200807478A 2005-10-31 2006-10-30 Фармацевтическая композиция, имеющая противоопухолевую активность, и способы UA97629C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0522082.7A GB0522082D0 (en) 2005-10-31 2005-10-31 Formulations
PCT/GB2006/050362 WO2007052076A2 (en) 2005-10-31 2006-10-30 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Publications (1)

Publication Number Publication Date
UA97629C2 true UA97629C2 (ru) 2012-03-12

Family

ID=35515969

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200807478A UA97629C2 (ru) 2005-10-31 2006-10-30 Фармацевтическая композиция, имеющая противоопухолевую активность, и способы

Country Status (23)

Country Link
US (1) US9192568B2 (ru)
EP (1) EP1968592B1 (ru)
JP (1) JP5197373B2 (ru)
KR (1) KR101434230B1 (ru)
CN (1) CN101300011B (ru)
AT (1) ATE549023T1 (ru)
AU (1) AU2006310260C1 (ru)
CA (1) CA2625096C (ru)
DK (1) DK1968592T3 (ru)
ES (1) ES2383967T3 (ru)
GB (1) GB0522082D0 (ru)
HR (1) HRP20120478T1 (ru)
IL (1) IL190774A (ru)
NO (1) NO341057B1 (ru)
NZ (1) NZ567291A (ru)
PL (1) PL1968592T3 (ru)
PT (1) PT1968592E (ru)
RS (1) RS52312B (ru)
RU (1) RU2429845C2 (ru)
SI (1) SI1968592T1 (ru)
UA (1) UA97629C2 (ru)
WO (1) WO2007052076A2 (ru)
ZA (1) ZA200803420B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
NZ589270A (en) * 2008-05-16 2011-12-22 Pharma Mar Sa Multiple myeloma treatments
KR20110025178A (ko) * 2008-05-16 2011-03-09 파르마 마르 에스.에이. Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
SI2701720T1 (sl) * 2011-04-28 2017-11-30 Oncopeptides Ab Liofilizirani pripravek citotoksičnih dipeptidov
WO2014065751A1 (en) 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
WO2022186221A1 (ja) * 2021-03-03 2022-09-09 国立大学法人東京大学 マクロ環含有新規テトラヒドロイソキノリンアルカロイド化合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
DE19605212A1 (de) * 1996-02-13 1997-08-14 Basf Ag Phosphordotiertes Silberkatalysator-Festbett
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
JP4562815B2 (ja) 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
CZ301083B6 (cs) * 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
KR100643092B1 (ko) 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
JP5219323B2 (ja) 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
HUP0600031A3 (en) * 2000-10-31 2012-02-28 Pharma Mar Kahalalide formulations and their use
CA2447553A1 (en) * 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
EA005564B1 (ru) * 2000-11-06 2005-04-28 Фарма Мар, С.А. Эффективные противоопухолевые лекарственные средства
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
SK10602003A3 (en) * 2001-03-06 2004-10-05 Bristol Myers Squibb Co Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
US20030027799A1 (en) 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7251892B2 (en) * 2003-07-09 2007-08-07 Temper Corporation Bearing assembly spacer adjustable system and method for adjusting a spacer
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CN1897949A (zh) 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
WO2005118584A2 (en) * 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
WO2006066183A2 (en) * 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
DE602006020335D1 (de) * 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
MX2008014404A (es) * 2006-05-12 2008-11-27 Pharma Mar Sa Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.

Also Published As

Publication number Publication date
PT1968592E (pt) 2012-06-18
AU2006310260B2 (en) 2012-08-09
NO341057B1 (no) 2017-08-14
HRP20120478T1 (hr) 2012-07-31
IL190774A (en) 2013-11-28
NO20082425L (no) 2008-07-25
SI1968592T1 (sl) 2012-10-30
ES2383967T3 (es) 2012-06-27
WO2007052076A2 (en) 2007-05-10
AU2006310260C1 (en) 2013-09-19
NZ567291A (en) 2011-04-29
ZA200803420B (en) 2009-10-28
IL190774A0 (en) 2008-11-03
EP1968592A2 (en) 2008-09-17
WO2007052076A3 (en) 2008-03-20
CA2625096A1 (en) 2007-05-10
EP1968592B1 (en) 2012-03-14
JP5197373B2 (ja) 2013-05-15
KR101434230B1 (ko) 2014-08-26
CA2625096C (en) 2015-11-24
US9192568B2 (en) 2015-11-24
DK1968592T3 (da) 2012-07-02
AU2006310260A1 (en) 2007-05-10
CN101300011B (zh) 2011-12-28
ATE549023T1 (de) 2012-03-15
CN101300011A (zh) 2008-11-05
KR20080064959A (ko) 2008-07-10
JP2009513618A (ja) 2009-04-02
GB0522082D0 (en) 2005-12-07
US20090076016A1 (en) 2009-03-19
RU2008121716A (ru) 2009-12-10
RS52312B (sr) 2012-12-31
RU2429845C2 (ru) 2011-09-27
PL1968592T3 (pl) 2012-08-31
HK1122743A1 (en) 2009-07-17

Similar Documents

Publication Publication Date Title
TW200621256A (en) Formulations
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
IL190774A0 (en) Pharmaceutical compositions containing a jorumycin-renieramycin-or saframycin-related compounds for treating proliferative diseases
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
MX2009002995A (es) Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico.
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
MY179392A (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BRPI0916356A2 (ru)
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
CL2008000495A1 (es) Compuestos derivados de tetrahidro-pirazolo[4,3-c]piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alergias, inflamacion, dolor, cancer, entreotras.
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina
GB0515025D0 (en) Organic compounds
CL2008001974A1 (es) Compuestos derivados de ciclopenta[d]pirimidina inhibidores de la quinasa akt; proceso de preparacion; kit farmaceutico; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, hiperproliferativas, cardiovasculares, neurode genarativas, entre otras.
DE602007009396D1 (en) Camptothecinderivate mit antitumorwirkung
HK40031579A (en) Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer